SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK-Reference-Cited by-同舟云学术

SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK

Published:2022-03-25 Issue:13 Volume:16 Page:2558-2574
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Shi Xiu¹²³^ORCID,Yu Xuejiao⁴,Wang Juan¹,Bian Shimin¹,Li Qiutong¹^ORCID,Fu Fengqing²³,Zou Xinwei¹,Zhang Lin¹,Bast Robert C.⁵,Lu Zhen⁵,Guo Lingchuan⁶,Chen Youguo¹²,Zhou Jinhua¹²

Affiliation:

1. Department of Obstetrics and Gynecology The First Affiliated Hospital of Soochow University Suzhou China

2. Clinical Research Center of Obstetrics and Gynecology Jiangsu Key Laboratory of Clinical Immunology Soochow University Suzhou China

3. Jiangsu Institute of Clinical Immunology The First Affiliated Hospital of Soochow University Suzhou China

4. Department of Imaging Department The First Affiliated Hospital of Soochow University Suzhou China

5. Department of Experimental Therapeutics University of Texas M.D. Anderson Cancer Center Houston TX USA

6. Department of Pathology The First Affiliated Hospital of Soochow University Suzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.13208

Reference37 articles.

1. Cancer statistics, 2019

2. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

3. Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread

4. Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in the expression of cell interaction-related pathways during brain metastasis in lung adenocarcinoma: Gene expression and immunohistochemical analysis;Pathology - Research and Practice;2024-08

2. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer;Drug Resistance Updates;2024-05

3. Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in PreclinicalIn VivoModels: Identification of Targets and New Modalities for Therapeutic Intervention;Cancer Genomics - Proteomics;2024-04-26

4. IGF2BP3-mediated enhanced stability of MYLK represses MSC adipogenesis and alleviates obesity and insulin resistance in HFD mice;Cellular and Molecular Life Sciences;2024-01-10

5. Reclassify High-Grade Serous Ovarian Cancer Patients Into Different Molecular Subtypes With Discrepancy Prognoses and Therapeutic Responses Based on Cancer-Associated Fibroblast-Enriched Prognostic Genes;Biomedical Engineering and Computational Biology;2024-01